These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2250300)

  • 21. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin.
    Meczes EL; Pearson AD; Austin CA; Tilby MJ
    Br J Cancer; 2002 Feb; 86(3):485-9. PubMed ID: 11875719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of genes differentially expressed in V79 cells grown as multicell spheroids.
    Oloumi A; Lam W; Banáth JP; Olive PL
    Int J Radiat Biol; 2002 Jun; 78(6):483-92. PubMed ID: 12065053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repair and proliferation: major determinants of the multifraction radiation response.
    Durand RE
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1147-52. PubMed ID: 3182347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP; Ou X
    Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
    Yamada SM; Yamada S; Takahashi H; Teramoto A; Nakayama H
    J Neurooncol; 2005 Feb; 71(3):259-65. PubMed ID: 15735914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
    Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
    Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative distinction of cisplatin-sensitive and -resistant mouse fibrosarcoma cells grown in multicell tumor spheroids.
    Frenzel KR; Saller RM; Kummermehr J; Schultz-Hector S
    Cancer Res; 1995 Jan; 55(2):386-91. PubMed ID: 7812971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
    Okamoto K; Okamoto I; Takeda M; Kobayashi S; Takeda K; Nakamatsu K; Nishimura Y; Nakagawa K
    Jpn J Clin Oncol; 2014 Aug; 44(8):743-8. PubMed ID: 24868080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
    Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly K
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):11-5. PubMed ID: 9007114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung.
    Yeh KH; Cheng AL
    Anticancer Res; 1997; 17(2B):1341-3. PubMed ID: 9137495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma].
    Uchida T; Okamoto K; Nishikawa K; Takahashi K
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):75-9. PubMed ID: 3753643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules.
    Haim N; Tsalik M; Robinson E
    Oncology; 1994; 51(1):102-7. PubMed ID: 8265093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
    Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.